Tocqueville Asset Management L.P. bought a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO) in the third quarter, HoldingsChannel reports. The firm bought 14,000 shares of the medical research company’s stock, valued at approximately $268,000.

Other large investors also recently modified their holdings of the company. NEXT Financial Group Inc boosted its position in shares of NeoGenomics by 200.0% during the second quarter. NEXT Financial Group Inc now owns 2,700 shares of the medical research company’s stock worth $59,000 after acquiring an additional 1,800 shares during the last quarter. Captrust Financial Advisors bought a new position in shares of NeoGenomics during the second quarter worth $66,000. Nisa Investment Advisors LLC boosted its position in shares of NeoGenomics by 867.5% during the third quarter. Nisa Investment Advisors LLC now owns 3,870 shares of the medical research company’s stock worth $74,000 after acquiring an additional 3,470 shares during the last quarter. Winslow Evans & Crocker Inc. bought a new position in shares of NeoGenomics during the second quarter worth $92,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of NeoGenomics by 14.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,778 shares of the medical research company’s stock worth $110,000 after acquiring an additional 739 shares during the last quarter. Hedge funds and other institutional investors own 85.02% of the company’s stock.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research report on Tuesday. BidaskClub upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Raymond James increased their price objective on shares of NeoGenomics from $23.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, July 31st. Leerink Swann set a $30.00 price objective on shares of NeoGenomics and gave the company a “buy” rating in a research report on Wednesday, July 31st. Finally, Benchmark set a $27.00 price objective on shares of NeoGenomics and gave the company a “buy” rating in a research report on Wednesday, July 31st. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. NeoGenomics has a consensus rating of “Buy” and a consensus price target of $24.86.

In related news, insider William Bonello sold 17,000 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $24.83, for a total value of $422,110.00. Following the transaction, the insider now owns 23,735 shares of the company’s stock, valued at approximately $589,340.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Robert J. Shovlin sold 70,473 shares of the firm’s stock in a transaction dated Thursday, October 31st. The stock was sold at an average price of $23.11, for a total transaction of $1,628,631.03. Following the completion of the transaction, the insider now directly owns 251,914 shares in the company, valued at approximately $5,821,732.54. The disclosure for this sale can be found here. Insiders sold a total of 311,843 shares of company stock worth $7,646,311 in the last ninety days. 8.80% of the stock is currently owned by insiders.

NeoGenomics stock opened at $22.01 on Friday. The firm has a market capitalization of $2.44 billion, a PE ratio of 169.31 and a beta of 0.94. NeoGenomics, Inc. has a 12-month low of $11.05 and a 12-month high of $26.89. The firm has a 50-day moving average price of $20.66 and a 200-day moving average price of $22.50. The company has a current ratio of 4.24, a quick ratio of 4.05 and a debt-to-equity ratio of 0.24.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, October 29th. The medical research company reported $0.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.01. The company had revenue of $104.70 million for the quarter, compared to the consensus estimate of $99.38 million. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. The firm’s revenue was up 51.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.05 EPS. As a group, sell-side analysts predict that NeoGenomics, Inc. will post 0.19 earnings per share for the current fiscal year.

NeoGenomics Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

See Also: Back-End Load

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.